The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis.
Matteo FerroFrancesco Del GiudiceGiuseppe CarrieriGian Maria BusettoLuigi CormioRodolfo HurleRoberto ContieriDavide ArcanioloAlessandro SciarraMartina MaggiFrancesco PorpigliaMatteo ManfrediCristian FioriAlessandro AntonelliAlessandro TafuriPierluigi BoveCarlo TerroneMarco BorghesiElisabetta CostantiniEster IlianoEmanuele MontanariLuca BoeriGiorgio Ivan RussoMassimo MadoniaAlessandro TeddeAlessandro VecciaClaudio SimeoneGiovanni LiguoriCarlo TrombettaEugenio BrunocillaRiccardo SchiavinaFabrizio Dal MoroMarco RacioppiMihai Dorin VartolomeiNicola LongoLorenzo SpiritoFelice CrocettoFrancesco CantielloRocco DamianoSavino M Di StasiMichele MarchioniLuigi SchipsPaolo ParmaLuca CarmignaniAndrea ContiFrancesco SoriaPaolo GonteroBiagio BaroneFederico DehoEmanuele ZaffutoRocco PapaliaRoberto M ScarpaVincenzo PagliaruloGiuseppe LucarelliPasquale DitonnoFrancesco Maria Gerardo BotticelliGennaro MusiMichele CatellaniOttavio de CobelliPublished in: Cancers (2021)
The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.